These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 27599425)

  • 61. [Mass-Production of Tumor Antigen-Specific Cytotoxic T Lymphocytes Using the iPS Cell Technology-Development of "Off-the-Shelf T Cells"for the Use in Allogeneic Transfusion Settings].
    Kawamoto H; Nagano S
    Gan To Kagaku Ryoho; 2019 Nov; 46(11):1677-1682. PubMed ID: 31748471
    [TBL] [Abstract][Full Text] [Related]  

  • 62. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
    Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
    Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Directed differentiation of induced pluripotent stem cells towards T lymphocytes.
    Lei F; Haque R; Xiong X; Song J
    J Vis Exp; 2012 May; (63):e3986. PubMed ID: 22617911
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model.
    Oflazoglu E; Elliott M; Takita H; Ferrone S; Henderson RA; Repasky EA
    J Transl Med; 2007 Jun; 5():29. PubMed ID: 17592641
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cloning and expansion of antigen-specific T cells using iPS cell technology: development of "off-the-shelf" T cells for the use in allogeneic transfusion settings.
    Kawamoto H; Masuda K; Nagano S; Maeda T
    Int J Hematol; 2018 Mar; 107(3):271-277. PubMed ID: 29388165
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Regeneration of antigen-specific T cells by using induced pluripotent stem cell (iPSC) technology.
    Kawamoto H; Masuda K; Nagano S
    Int Immunol; 2021 Nov; 33(12):827-833. PubMed ID: 34661676
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Tumor-rejection antigens expressed on human squamous cell carcinoma].
    Itoh K; Nakao M; Imai Y; Toh Y; Yamana H
    Hum Cell; 1995 Dec; 8(4):149-54. PubMed ID: 8721083
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
    Suzuki M; Curran KJ; Cheung NK
    Pediatr Blood Cancer; 2015 Aug; 62(8):1326-36. PubMed ID: 25832831
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.
    Toes RE; Offringa R; Feltkamp MC; Visseren MJ; Schoenberger SP; Melief CJ; Kast WM
    Behring Inst Mitt; 1994 Jul; (94):72-86. PubMed ID: 7998917
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Tumor specific antigen and cytotoxic T lymphocytes].
    Uenaka A; Nakayama E
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():568-73. PubMed ID: 15861712
    [No Abstract]   [Full Text] [Related]  

  • 71. [Regeneration of tumor antigen-specific CTLs utilizing iPS technology].
    Maeda T; Masuda K; Kawamoto H
    Rinsho Ketsueki; 2016 Aug; 57(8):1066-73. PubMed ID: 27599425
    [TBL] [Abstract][Full Text] [Related]  

  • 72.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.